AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oramed Pharmaceuticals Inc. Director's Dealing 2024

Apr 18, 2024

6965_dirs_2024-04-18_995ae189-1a78-4d0f-aedd-d111278aa874.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2024-04-17

Reporting Person: Reznick Yehuda (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-04-17	Common Stock	A	29800	—	Acquired	29800	Direct

Footnotes

F1: Represents (i) a grant of 22,500 Restricted Stock Units ("RSUs") that will vest in equal installments on January 1, 2025, January 1, 2026 and January 1, 2027 and (ii) grants of 5,070 and 2,230 RSUs that will each vest in nearly equal installments on July 1, 2024, October 1, 2024 and January 1, 2025. In each case, the RSUs convert into the Issuer's Common Stock on a one-for-one basis.